



SLOVENSKI STANDARD SIST EN 50527-2-2:2018

01-oktober-2018

Postopek ocenjevanja izpostavljenosti delavcev z aktivnimi medicinskimi vsadki elektromagnetnim poljem - 2-2. del: Specifično ocenjevanje delavcev s kardioverter-defibrilatorjem (ICD)

Procedure for the assessment of the exposure to electromagnetic fields of workers bearing active implantable medical devices - Part 2-2: Specific assessment for workers with cardioverter defibrillators (ICDs)

iTeh STANDARD PREVIEW
(standards.iteh.ai)

Procédure pour l'évaluation de l'exposition des travailleurs porteurs de dispositifs médicaux implantables actifs aux champs électromagnétiques - Partie 2-2 : Evaluation spécifique aux travailleurs porteurs de défibrillateurs automatiques implantables

Ta slovenski standard je istoveten z: EN 50527-2-2:2018

ICS:

11.040.40	Implantanti za kirurgijo, protetiko in ortetiko	Implants for surgery, prosthetics and orthotics
17.240	Merjenje sevanja	Radiation measurements

SIST EN 50527-2-2:2018

en

iTeh STANDARD PREVIEW
(standards.iteh.ai)

SIST EN 50527-2-2:2018

<https://standards.iteh.ai/catalog/standards/sist/78e7c5ab-6f12-42f6-91a0-15ba29aebc5f/sist-en-50527-2-2-2018>

EUROPEAN STANDARD

EN 50527-2-2

NORME EUROPÉENNE

EUROPÄISCHE NORM

May 2018

ICS 11.040.40; 17.240

English Version

Procedure for the assessment of the exposure to
electromagnetic fields of workers bearing active implantable
medical devices - Part 2-2: Specific assessment for workers with
cardioverter defibrillators (ICDs)

Procédure pour l'évaluation de l'exposition des travailleurs
porteurs de dispositifs médicaux implantables actifs aux
champs électromagnétiques - Partie 2-2 : Evaluation
spécifique aux travailleurs porteurs de défibrillateurs
automatiques implantables

Verfahren zur Beurteilung der Exposition von
Arbeitnehmern mit aktiven implantierbaren medizinischen
Geräten gegenüber elektromagnetischen Feldern - Teil 2-2:
Besondere Beurteilung für Arbeitnehmer mit Cardioverter-
Defibrillatoren (ICDs)

This European Standard was approved by CENELEC on 2018-04-03. CENELEC members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration.

Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CENELEC member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CENELEC member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CENELEC members are the national electrotechnical committees of Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.



European Committee for Electrotechnical Standardization
Comité Européen de Normalisation Electrotechnique
Europäisches Komitee für Elektrotechnische Normung

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

Contents	Page
European foreword	5
1 Scope	6
2 Normative references	6
3 Terms and definitions	7
4 Specific assessment	8
4.1 Description of the assessment process	8
4.1.1 General	8
4.1.2 Equipment consideration	11
4.1.3 Patient warning consideration	11
4.1.4 Cases for additional investigation	11
4.1.5 Choice of investigative method	14
4.2 Clinical investigation	15
4.3 Non-clinical investigation	16
4.3.1 General	16
4.3.2 Non-clinical investigation by <i>in vitro</i> testing	16
4.3.3 Non-clinical investigation by comparative study	19
5 Documentation	20
Annex A (normative) Device specific replacement of EN 50527-1:2016, Table 1	21
Annex B (informative) Clinical investigation methods	27
B.1 Assessment of device compatibility using stored data and diagnostic features	27
B.2 Real time event monitoring by telemetry	27
Annex C (informative) <i>in vitro</i> testing/measurements	28
C.1 Introduction	28
C.2 EM phantom	28
C.2.1 General	28
C.2.2 EM phantom design	28
C.3 Basic procedure for device <i>in vitro</i> testing	29
Annex D (informative) Modelling — Field modelling or calculations	31
Annex E (informative) Interference from Low-Frequency Magnetic and Electric Fields (1 Hz to 10 MHz) Including Application to 50 Hz Power-Frequency	32
E.1 Introduction	32
E.2 Implanted devices and leads	32
E.3 Sensitivity of devices to interference	33
E.4 Immunity requirements	33
E.5 Voltage induced in the leads by magnetic fields	34
E.5.1 Induction in a loop	34
E.5.2 Inductive loop area for bipolar leads	34
E.5.3 Voltage induced in leads	36
E.6 Voltage induced in the leads by electric fields	36
E.7 Values of 50 Hz magnetic and electric field that can cause interference	38
E.8 Factors that affect the immunity from interference	38
E.8.1 Reasons for improved immunity	38
E.8.2 Adjustment for device sensitivity setting	39
E.8.3 Adjustment for lead tip to ring spacing	41
E.9 Application to Power Frequency Exposure Situations	42
E.9.1 Public exposures	42
E.9.2 Beneath high voltage power lines	42
E.9.3 Occupational settings	43
E.9.4 Temporary exposure above the interference levels	43
E.9.5 Induced voltages at occupational exposure limit values	44

E.10	Conversion based on known compliance with basic restrictions	44
E.10.1	General.....	44
E.10.2	Relationship between magnetic fields and induced current density.....	45
E.10.3	Relationship between magnetic fields and induced voltages on an implanted lead	46
E.10.4	A simple model to analyse the possible voltages at device terminations generated from induced current density equivalent the basic restrictions of Council Recommendation 1999/519/EC	46
Annex F	(informative) Determination of minimum immunity for radio-frequency fields	49
F.1	Determination of immunity from the field	49
F.1.1	General.....	49
F.1.2	Intermediate frequencies (5 MHz to 30 MHz)	49
F.1.3	High frequency (above 30 MHz)	50
F.2	References	51
Annex G	(informative) Obtaining the device immunity and guidelines provided by device manufacturers –	52
G.1	Introduction.....	52
G.2	EMC and devices – General guidelines, hazards and harms.....	52
G.3	Induced voltages, fields and zones	55
G.3.1	Induced voltage test levels	55
G.3.2	Magnetic field amplitudes producing test limits	55
G.3.3	Induced voltage zones	57
G.3.4	Magnetic field zones.....	58
Bibliography	60

iTech STANDARD PREVIEW

(standards.iteh.ai)

Figures		
Figure 1	— Overview of the assessment process	9
Figure 2	— Specific assessment process	10
Figure 3	— Additional investigation process	13
Figure 4	— Comparison process	18
Figure C.1	— Example of <i>in vitro</i> procedure for EM interference at low frequency using planar electrodes, bipolar lead and ECG and data recording.....	30
Figure E.1	— Typical implantations of cardiac devices	32
Figure E.2	— Effective induction area of an open wire loop inside a conductive medium	35
Figure E.3	— Schematic representation of bipolar pickup of interference in an infinitely homogeneous conducting medium.....	35
Figure E.4	— Showing how the immunity ratio affects magnetic field that can result in interference	40
Figure E.5	— Showing how the immunity ratio affects electric field that can result in interference ...	40
Figure E.6	— Showing how the tip to ring spacing affects the magnetic field that can result in interference	41
Figure E.7	— Showing how the tip to ring spacing affects the electric field that can result in interference	42
Figure E.8	— Eddy-current inside a conductive medium induced by varying magnetic flux	45
Figure E.9	— Voltage induced on a lead inside conductive body tissue	46
Figure E.10	— Voltages on an implanted lead.....	47
Figure G.1	— Induced voltage test levels	55
Figure G.2	— Magnetic field amplitudes, for frequencies below 10 000 kHz, producing test limits in bipolar configurations.....	56
Figure G.3	— Induced voltage zones for bipolar configurations.....	57
Figure G.4	— Induced voltage zones for bipolar configurations.....	58

EN 50527-2-2:2018 (E)

Figure G.5 — Magnetic field zones, for frequencies below 10 000 kHz for bipolar configurations 59

Tables

Table A.1 — Compliant workplaces and equipment with exceptions	21
Table E.1 — Values of 50 Hz electric and magnetic field (r.m.s.) that might, under unfavourable circumstances, cause interference with devices	38
Table E.2 — Summary of typical maximum field values beneath high-voltage overhead lines and corresponding voltage induced in the device	43
Table E.3 a) — Voltage induced in bipolar leads by the health effects ELV where f is in Hz	44
Table E.3 b) — Voltage induced in bipolar leads by the sensory effects ELV, where f is in Hz. It is defined only up to 400 Hz.....	44

iTeh STANDARD PREVIEW
(standards.iteh.ai)

[SIST EN 50527-2-2:2018](https://standards.iteh.ai/catalog/standards/sist/78e7c5ab-6f12-42f6-91a0-15ba29aebc5f/sist-en-50527-2-2-2018)

<https://standards.iteh.ai/catalog/standards/sist/78e7c5ab-6f12-42f6-91a0-15ba29aebc5f/sist-en-50527-2-2-2018>

European foreword

This document (EN 50527-2-2:2018) has been prepared by CLC/TC 106X "Electromagnetic fields in the human environment".

The following dates are fixed:

- latest date by which this document has to be implemented at national level by publication of an identical national standard or by endorsement (dop) 2019-04-03
- latest date by which the national standards conflicting with this document have to be withdrawn (dow) 2021-04-03

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CENELEC shall not be held responsible for identifying any or all such patent rights.

This document has been prepared under a mandate given to CENELEC by the European Commission and the European Free Trade Association.

iTeh STANDARD PREVIEW (standards.iteh.ai)

[SIST EN 50527-2-2:2018](https://standards.iteh.ai/catalog/standards/sist/78e7c5ab-6f12-42f6-91a0-15ba29aebc5f/sist-en-50527-2-2-2018)

<https://standards.iteh.ai/catalog/standards/sist/78e7c5ab-6f12-42f6-91a0-15ba29aebc5f/sist-en-50527-2-2-2018>

EN 50527-2-2:2018 (E)**1 Scope**

This European Standard provides the procedure for the specific assessment required in EN 50527-1:2016, Annex A, for workers with implanted cardioverter defibrillators (ICDs) and Cardiac Resynchronization Therapy devices with associated defibrillation functions (CRT-D). Only devices of this type equipped with leads implanted transvenously are considered. It offers different approaches for doing the risk assessment.

NOTE 1 If the worker has other Active Implantable Medical Devices (AIMDs) implanted additionally, they are assessed separately according to EN 50527-1 or other particular standards within the EN 50527 series.

NOTE 2 The risks to patients due to interference with pacing functions associated with CRT-D devices are assessed using EN 50527-2-1.

The purpose of the specific assessment is to determine the risk for workers with implanted ICDs and CRT-Ds arising from exposure to electromagnetic fields (EMF) at the workplace. The assessment includes the likelihood of clinically significant effects and takes account of both transient and long-term exposure within specific areas of the workplace.

NOTE 3 This standard does not address risks from contact currents.

The techniques described in the different approaches may also be used for the assessment of publicly accessible areas.

The frequency range to be observed is from 0 Hz to 3 GHz. Above 3 GHz no interference with the devices within the scope of this Particular Standard is expected to occur when the exposure limits are not exceeded.

NOTE 4 The rationale for limiting the observation range to 3 GHz can be found in ISO 14117:2012, Clause 5.

NOTE 5 Further information concerning the functions of Pacemakers, CRT-D, and ICD devices can be found in Ellenbogen and Kaszala, 2014.

2 Normative references

SIST EN 50527-2-2:2018

<https://standards.iteh.ai/catalog/standards/sist/78e7c5ab-6f12-42f6-91a0-15ba29aebc5f/sist-en-50527-2-2-2018>

The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

EN 45502-2-2:2008, *Active implantable medical devices — Part 2-2: Particular requirements for active implantable medical devices intended to treat tachyarrhythmia (includes implantable defibrillators)*

EN 50527-1:2016, *Procedure for the assessment of the exposure to electromagnetic fields of workers bearing active implantable medical devices — Part 1: General*

EN ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice (ISO 14155)*

ISO 14117:2012, *Active implantable medical devices — Electromagnetic compatibility — EMC test protocols for implantable cardiac pacemakers, implantable cardioverter defibrillators and cardiac resynchronization devices*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in EN 50527-1:2016 and the following apply.

3.1

implantable pulse generator (IPG)

part of the ACTIVE IMPLANTABLE MEDICAL DEVICE, including the power supply and electronic circuit that produces an electrical output

Note 1 to entry: For the purposes of this Particular Standard, the term IMPLANTABLE PULSE GENERATOR describes any ACTIVE IMPLANTABLE MEDICAL DEVICE that incorporates functions intended to treat tachyarrhythmias.

3.2

implantable cardioverter defibrillator (ICD)

ACTIVE IMPLANTABLE MEDICAL DEVICE comprising an IMPLANTABLE PULSE GENERATOR and LEAD(S) that is intended to detect and correct tachycardias and fibrillation by application of CARDIOVERSION/DEFIBRILLATION PULSE(S) to the heart

3.3

electrode

electrically conducting part (usually the termination of a lead) which is designed to form an interface with body tissue or body fluid

3.4

bipolar lead

lead with two electrodes that are electrically isolated from each other

3.5

AIMD-Employee

worker with an active implantable medical device

Note 1 to entry: For the purposes of this Particular Standard, the term AIMD-Employee refers to the patient whose implant is of type ICD or CRT-D.

3.6

assessment team

team consisting of:

- employer and if applicable, his occupational health and safety experts and/or occupational physician,
- AIMD-Employee and his responsible physician,
- (technical and medical) experts as necessary, e.g. manufacturer of the device

3.7

implantable cardiac resynchronization therapy/defibrillator device

CRT-D

active implantable medical device intended to detect and correct tachycardias and fibrillation by application of cardioversion/defibrillation pulses to the heart, and to provide improved ventricular activation to optimize cardiac output

3.8

anti-tachycardia pacing

ATP

therapy function associated with CRT-D devices consisting of pacing pulses delivered to the heart to interrupt a tachyarrhythmia episode and restore normal sinus rhythm

EN 50527-2-2:2018 (E)**3.9****EM phantom**

physical model containing tissue-equivalent material used to simulate the body in an experimental dose measurement (from World Health Organization)

Note 1 to entry: EM phantoms are sometimes also referred to as torso simulator or phantom.

3.10**uninfluenced behaviour**

conditions for uninfluenced behaviour are provided in EN 50527-1:2016, 4.1.3

3.11**device**

<in the context of this standard> either the implanted ICD or CRT-D device

4 Specific assessment**4.1 Description of the assessment process****4.1.1 General**

The risk assessment is based on the approach that, according to EN 45502-2-2 and ISO 14117, ICDs and CRT-Ds are expected to work uninfluenced as long as the General Public Reference levels of Council Recommendation 1999/519/EC are not exceeded (except for static magnetic fields and for pulsed high frequency electromagnetic fields EMF) (see also F.7).

NOTE Throughout the remainder of this standard, the General Public Reference Levels of Council Recommendation 1999/519/EC are referred to as "reference levels" unless specified otherwise.

The EMC requirements within EN 45502-2-2 have been incorporated with updates into ISO 14117 and their use is recommended here: <https://standards.iteh.ai/catalog/standards/sist/78e7c5ab-6f12-42f6-91a0-15ba29aebc5f/sist-en-50527-2-2-2018>

Further risk assessment is not necessary if a history of uninfluenced behaviour at the workplace exists and a responsible physician has confirmed that this history is sufficient to exclude severe (clinically significant) interaction.

A specific risk assessment for the AIMD-Employee is required when there is history of influenced behaviour or one of the following three conditions is fulfilled:

- a) there is equipment present in the workplace that is neither included in, nor used in accordance with Table A.1;
- b) all equipment at the workplace is listed in Table A.1 (see Annex A) and is used accordingly, but the AIMD-Employee has received warning(s) from the responsible physician that their device might be susceptible to electromagnetic interference (EMI), thereby increasing the risk at the workplace. There are two types of warnings that can be given:
 - 1) patient-specific warnings provided by the responsible physician to the AIMD-Employee due to settings in effect that can cause changes in device behaviour in the presence of EMF that are below the reference levels; or
 - 2) general warnings supplied by the device manufacturer in accompanying documentation about recognized behaviour changes of the device when it is subjected to EMF generated by specific types of equipment;
- c) there is equipment present in the workplace that is neither included in, nor used in accordance with Table A.1 and for which the AIMD-Employee does have a history of uninfluenced behaviour while in its presence, but the AIMD-Employee has received a specific warning as described above.

In order to minimize the burden placed on the employer and AIMD-Employee, the assessment should begin with the investigation steps shown in Figure 1. The steps to be taken are based upon whether the specific assessment is the result of an equipment issue or a patient warning issue.

When only condition a) exists, then 4.1.2 shall apply. When only condition b) exists, then 4.1.3 shall apply. When condition c) exists, then both 4.1.2 and 4.1.3 shall apply.

When a device is tested according to EN 45502–2-2, the manufacturer is required to provide a warning to the implanting physician in the accompanying technical information as to any sensitivity settings available in the device that if used, afford the device with a reduced immunity to certain types of EMI. A specific warning would only be given to the patient receiving the implant if they were discharged with one of these settings in effect, or if at follow-up, a change to one of these settings was made for clinical reasons.

For equipment included in and used per Table A.1					Legend	
History		Influenced Behaviour	Un-influenced Behaviour	No History available	1	Further risk assessment is not necessary
Warning from responsible Physician ?	Yes	2	3	2		
	No	2	1	1	3	further risk assessment unnecessary if responsible physician has confirmed that this history is sufficient to exclude clinically significant interaction
For Equipment not included in or not used per Table A.1						
Specific risk assessment for the AIMD-Employee is required						

Figure 1 — Overview of the assessment process




Figure 2 — Specific assessment process

4.1.2 Equipment consideration

Information relevant to the equipment or other field generating sources under consideration shall be collected to answer sufficiently the following two questions:

- can it be determined that clinically significant interference with the device will not occur as a result of expected exposure to the equipment under consideration? If so, no further assessment is required and documentation of the result can proceed, as required in Clause 5;
- can it be determined that the AIMD-Employee can return to the workplace only with restrictions placed on the work tasks or areas of access? If so, no further assessment is required and documentation of the work restrictions can proceed as required in Clause 5.

When neither of these questions can be answered positively, additional investigation, hereafter referred to as “Case 1”, is required as specified in 4.1.4.

The intent of this clause is to find and utilize information that might already exist and that allows the assessment to be completed without further, more costly and time consuming effort. It is recommended that experts who are likely to have such information be contacted. Examples of such experts are the device manufacturer, equipment manufacturer, employer’s technical department, consultants, or others skilled in EMI effects with implanted devices.

4.1.3 Patient warning consideration

The responsible physician and AIMD-Employee shall be consulted to determine the type of and details for any EMI warnings applicable to the device.

If the warning is about behaviour of the device due to interference from particular types of equipment (see 4.1.1 b) 2)) then it shall first be determined whether that equipment is actually present in the workplace:

- if the equipment is not present, the AIMD-Employee is allowed to work without restrictions and the specific assessment can be completed and documented as required in Clause 5.
- if the equipment subject to the warning is present, the steps given in 4.1.2 shall be taken.

If the warning is due to the applied settings of the device that might cause reduced immunity (see 4.1.1 b) 1)) to EMI that is at or below the reference levels, the responsible physician shall be consulted to determine whether the settings can be changed to avoid settings that are associated with the warning, thereby restoring standard immunity levels:

- if it is determined that such a change of settings can be made, the AIMD-Employee shall be advised to arrange, through consultation with the responsible physician, for these changes of settings to be made prior to returning to work. When the change of setting has been completed, the AIMD-Employee is allowed to work without restrictions. The results shall be documented as required in Clause 5 and the assessment is concluded;
- if the settings cannot be changed, then additional investigation, hereafter referred to as “Case 2” is required as discussed in 4.1.4.

4.1.4 Cases for additional investigation

When the investigation steps shown in Figure 2 have been followed but fail to mitigate or to dismiss risk to the AIMD-Employee from the effects of workplace EMI, then an additional investigation shall be performed as shown in Figure 3 and described in 4.1.5. The goal of the investigation is to determine the likelihood of a clinically significant response of the device to the EMI at the workplace that is the result of the following.

a) **Case 1:** Equipment is used at the workplace that is:

- 1) neither listed in, nor used in accordance with, Table A.1, and for which there is no information available that allows a pre-determination of safe or restricted work for the AIMD-Employee, or
- 2) capable of emitting fields that can induce device lead voltages exceeding the immunity levels established by conformity with the device product standard, EN 45502-2-2,

EN 50527-2-2:2018 (E)

- 3) known by the device manufacturer to potentially cause interference with the device and there is no applicable safe use guideline available from other sources.

iTeh STANDARD PREVIEW
(standards.iteh.ai)

SIST EN 50527-2-2:2018

<https://standards.iteh.ai/catalog/standards/sist/78e7c5ab-6f12-42f6-91a0-15ba29aebc5f/sist-en-50527-2-2-2018>




Figure 3 — Additional investigation process